Royalty Pharma plc EBITDA for the Trailing 12 Months (TTM) ending March 31, 2025: USD 2.33 B

Royalty Pharma plc EBITDA is USD 2.33 B for the Trailing 12 Months (TTM) ending March 31, 2025, a 81.93% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Royalty Pharma plc EBITDA for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 1.28 B, a 69.35% change year over year.
  • Royalty Pharma plc EBITDA for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 755.95 M, a -44.75% change year over year.
  • Royalty Pharma plc EBITDA for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 1.37 B, a -12.25% change year over year.
  • Royalty Pharma plc EBITDA for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 1.56 B, a -39.48% change year over year.
Key Data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)